15.05.2019 • News

Bionure Appoints Lucia Septien as Chief Medical Officer

Bionure has appointed Lucia Septien as chief medical officer. Source: Bionure
Bionure has appointed Lucia Septien as chief medical officer. Source: Bionure

Bionure, a Barcelona, Spain-based clinical stage R&D company specialized in the treatment of neurodegenerative diseases, has appointed Lucia Septien as chief medical officer (CMO).

Septien joins Bionure from DBV Technologies where she also held the CMO position. Prior to that, she worked as a clinical doctor in neurology and psychiatry and then held diverse roles at major pharmaceutical companies, including Pfizer, Wyeth, GSK, Servier and Ipsen.

"We warmly welcome Lucia to Bionure. With her sensitivity for patients, her solid experience in CNS drug development and her leadership skills, she will strengthen our team," said Laurent Nguyen, CEO of Bionure. “We are convinced of her ability to successfully implement our neuroprotection projects.”

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.